Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

HIGH expression of OSM and IL-6 are associated with decreased breast cancer survival: synergistic induction of IL-6 secretion by OSM and IL-1β.

Tawara K, Scott H, Emathinger J, Wolf C, LaJoie D, Hedeen D, Bond L, Montgomery P, Jorcyk C.

Oncotarget. 2019 Mar 12;10(21):2068-2085. doi: 10.18632/oncotarget.26699. eCollection 2019 Mar 12.

2.

IL-6 and ovarian cancer: inflammatory cytokines in promotion of metastasis.

Browning L, Patel MR, Horvath EB, Tawara K, Jorcyk CL.

Cancer Manag Res. 2018 Dec 5;10:6685-6693. doi: 10.2147/CMAR.S179189. eCollection 2018. Review.

3.

Co-Expression of VEGF and IL-6 Family Cytokines is Associated with Decreased Survival in HER2 Negative Breast Cancer Patients: Subtype-Specific IL-6 Family Cytokine-Mediated VEGF Secretion.

Tawara K, Scott H, Emathinger J, Ide A, Fox R, Greiner D, LaJoie D, Hedeen D, Nandakumar M, Oler AJ, Holzer R, Jorcyk C.

Transl Oncol. 2019 Feb;12(2):245-255. doi: 10.1016/j.tranon.2018.10.004. Epub 2018 Nov 12.

4.

OSM potentiates preintravasation events, increases CTC counts, and promotes breast cancer metastasis to the lung.

Tawara K, Bolin C, Koncinsky J, Kadaba S, Covert H, Sutherland C, Bond L, Kronz J, Garbow JR, Jorcyk CL.

Breast Cancer Res. 2018 Jun 14;20(1):53. doi: 10.1186/s13058-018-0971-5.

5.

DICER1 Syndrome: DICER1 Mutations in Rare Cancers.

Robertson JC, Jorcyk CL, Oxford JT.

Cancers (Basel). 2018 May 15;10(5). pii: E143. doi: 10.3390/cancers10050143. Review.

6.

Endoplasmic Reticulum Stress and Unfolded Protein Response in Cartilage Pathophysiology; Contributing Factors to Apoptosis and Osteoarthritis.

Hughes A, Oxford AE, Tawara K, Jorcyk CL, Oxford JT.

Int J Mol Sci. 2017 Mar 20;18(3). pii: E665. doi: 10.3390/ijms18030665. Review.

7.
8.

Cryoablation and Meriva have strong therapeutic effect on triple-negative breast cancer.

Chandra D, Jahangir A, Cornelis F, Rombauts K, Meheus L, Jorcyk CL, Gravekamp C.

Oncoimmunology. 2015 May 29;5(1):e1049802. eCollection 2016.

9.

The Effect of OSM on MC3T3-E1 Osteoblastic Cells in Simulated Microgravity with Radiation.

Goyden J, Tawara K, Hedeen D, Willey JS, Oxford JT, Jorcyk CL.

PLoS One. 2015 Jun 1;10(6):e0127230. doi: 10.1371/journal.pone.0127230. eCollection 2015.

10.

DNA topology influences molecular machine lifetime in human serum.

Goltry S, Hallstrom N, Clark T, Kuang W, Lee J, Jorcyk C, Knowlton WB, Yurke B, Hughes WL, Graugnard E.

Nanoscale. 2015 Jun 21;7(23):10382-90. doi: 10.1039/c5nr02283e.

11.

Oncostatin M binds to extracellular matrix in a bioactive conformation: implications for inflammation and metastasis.

Ryan RE, Martin B, Mellor L, Jacob RB, Tawara K, McDougal OM, Oxford JT, Jorcyk CL.

Cytokine. 2015 Mar;72(1):71-85. doi: 10.1016/j.cyto.2014.11.007. Epub 2015 Jan 23.

12.

Stüve-Wiedemann syndrome: LIFR and associated cytokines in clinical course and etiology.

Mikelonis D, Jorcyk CL, Tawara K, Oxford JT.

Orphanet J Rare Dis. 2014 Mar 12;9:34. doi: 10.1186/1750-1172-9-34. Review.

13.

Oncostatin m promotes mammary tumor metastasis to bone and osteolytic bone degradation.

Bolin C, Tawara K, Sutherland C, Redshaw J, Aranda P, Moselhy J, Anderson R, Jorcyk CL.

Genes Cancer. 2012 Feb;3(2):117-30. doi: 10.1177/1947601912458284.

14.

Novel mouse mammary cell lines for in vivo bioluminescence imaging (BLI) of bone metastasis.

Bolin C, Sutherland C, Tawara K, Moselhy J, Jorcyk CL.

Biol Proced Online. 2012 Apr 17;14(1):6. doi: 10.1186/1480-9222-14-6.

15.

Bleach gel: a simple agarose gel for analyzing RNA quality.

Aranda PS, LaJoie DM, Jorcyk CL.

Electrophoresis. 2012 Jan;33(2):366-9. doi: 10.1002/elps.201100335.

16.

Clinical significance of interleukin (IL)-6 in cancer metastasis to bone: potential of anti-IL-6 therapies.

Tawara K, Oxford JT, Jorcyk CL.

Cancer Manag Res. 2011;3:177-89. doi: 10.2147/CMR.S18101. Epub 2011 May 18.

17.

Kinetics of DNA and RNA Hybridization in Serum and Serum-SDS.

Graugnard E, Cox A, Lee J, Jorcyk C, Yurke B, Hughes WL.

IEEE Trans Nanotechnol. 2010 Sep 1;9(5):603-609.

18.

Collagen alpha1(XI) in normal and malignant breast tissue.

Halsted KC, Bowen KB, Bond L, Luman SE, Jorcyk CL, Fyffe WE, Kronz JD, Oxford JT.

Mod Pathol. 2008 Oct;21(10):1246-54. doi: 10.1038/modpathol.2008.129. Epub 2008 Jul 25.

19.

Oncostatin M induces cell detachment and enhances the metastatic capacity of T-47D human breast carcinoma cells.

Jorcyk CL, Holzer RG, Ryan RE.

Cytokine. 2006 Mar 21;33(6):323-36. Epub 2006 May 19.

PMID:
16713283
20.

Breast cancer cells stimulate neutrophils to produce oncostatin M: potential implications for tumor progression.

Queen MM, Ryan RE, Holzer RG, Keller-Peck CR, Jorcyk CL.

Cancer Res. 2005 Oct 1;65(19):8896-904.

21.

Involvement of HGF/SF-Met signaling in prostate adenocarcinoma cells: evidence for alternative mechanisms leading to a metastatic phenotype in Pr-14c.

MacDougall CA, Vargas M, Soares CR, Holzer RG, Ide AE, Jorcyk CL.

Prostate. 2005 Jul 1;64(2):139-48.

PMID:
15678502
22.

Oncostatin M stimulates the detachment of a reservoir of invasive mammary carcinoma cells: role of cyclooxygenase-2.

Holzer RG, Ryan RE, Tommack M, Schlekeway E, Jorcyk CL.

Clin Exp Metastasis. 2004;21(2):167-76.

PMID:
15168734
23.

Development and characterization of a progressive series of mammary adenocarcinoma cell lines derived from the C3(1)/SV40 Large T-antigen transgenic mouse model.

Holzer RG, MacDougall C, Cortright G, Atwood K, Green JE, Jorcyk CL.

Breast Cancer Res Treat. 2003 Jan;77(1):65-76.

PMID:
12602905
24.
25.

Development of PIN and prostate adenocarcinoma cell lines: a model system for multistage tumor progression.

Soares CR, Shibata MA, Green JE, Jorcyk CL.

Neoplasia. 2002 Mar-Apr;4(2):112-20.

26.

Suppression of mammary carcinoma growth in vitro and in vivo by inducible expression of the Cdk inhibitor p21.

Shibata MA, Yoshidome K, Shibata E, Jorcyk CL, Green JE.

Cancer Gene Ther. 2001 Jan;8(1):23-35.

28.

The C3(1)/SV40 T-antigen transgenic mouse model of mammary cancer: ductal epithelial cell targeting with multistage progression to carcinoma.

Green JE, Shibata MA, Yoshidome K, Liu ML, Jorcyk C, Anver MR, Wigginton J, Wiltrout R, Shibata E, Kaczmarczyk S, Wang W, Liu ZY, Calvo A, Couldrey C.

Oncogene. 2000 Feb 21;19(8):1020-7. Review.

29.

Heterotopic endochondrial ossification with mixed tumor formation in C3(1)/Tag transgenic mice is associated with elevated TGF-beta1 and BMP-2 expression.

Maroulakou IG, Shibata MA, Anver M, Jorcyk CL, Liu Ml, Roche N, Roberts AB, Tsarfaty I, Reseau J, Ward J, Green JE.

Oncogene. 1999 Sep 23;18(39):5435-47.

30.

Amplification of Ki-ras and elevation of MAP kinase activity during mammary tumor progression in C3(1)/SV40 Tag transgenic mice.

Liu ML, Von Lintig FC, Liyanage M, Shibata MA, Jorcyk CL, Ried T, Boss GR, Green JE.

Oncogene. 1998 Nov 5;17(18):2403-11.

31.

Expression of KAI1 in paraffin-embedded normal, hyperplastic and neoplastic prostate and prostate carcinoma cell lines.

Ward JM, Konishi N, Ohshima M, Lamb PW, Jorcyk CL, Barrett JC.

Pathol Int. 1998 Feb;48(2):87-92.

PMID:
9589471
32.

The C3(1)/SV40 T antigen transgenic mouse model of prostate and mammary cancer.

Shibata MA, Jorcyk CL, Liu ML, Yoshidome K, Gold LG, Green JE.

Toxicol Pathol. 1998 Jan-Feb;26(1):177-82. Review. No abstract available.

PMID:
9502400
33.

Altered expression of transforming growth factor betas during urethral and bulbourethral gland tumor progression in transgenic mice carrying the androgen-responsive C3(1) 5' flanking region fused to SV40 large T antigen.

Shibata MA, Jorcyk CL, Devor DE, Yoshidome K, Rulong S, Resau J, Roche N, Roberts AB, Ward JM, Green JE.

Carcinogenesis. 1998 Jan;19(1):195-205.

PMID:
9472712
34.

Genetic alterations in the development of mammary and prostate cancer in the C3(1)/Tag transgenic mouse model.

Yoshidome K, Shibata MA, Maroulakou IG, Liu ML, Jorcyk CL, Gold LG, Welch VN, Green JE.

Int J Oncol. 1998 Feb;12(2):449-53. Review.

PMID:
9458374
35.

Development and characterization of a mouse prostate adenocarcinoma cell line: ductal formation determined by extracellular matrix.

Jorcyk CL, Liu ML, Shibata MA, Maroulakou IG, Komschlies KL, McPhaul MJ, Resau JH, Green JE.

Prostate. 1998 Jan 1;34(1):10-22.

PMID:
9428383
36.

Reduced p53 dosage associated with mammary tumor metastases in C3(1)/TAG transgenic mice.

Maroulakou IG, Shibata MA, Jorcyk CL, Chen XX, Green JE.

Mol Carcinog. 1997 Oct;20(2):168-74.

PMID:
9364206
37.

Multiple regulatory regions control the expression of Ets-1 in the developing mouse: vascular expression conferred by intron I.

Jorcyk CL, Garrett LJ, Maroulakou IG, Watson DK, Green JE.

Cell Mol Biol (Noisy-le-grand). 1997 Mar;43(2):211-25.

PMID:
9130605
38.

Evaluation of the antitumor activity of the interleukin-12/pulse interleukin-2 combination.

Wigginton JM, Komschlies KL, Green JE, Cox GW, Jorcyk CL, Back TC, Franco JL, Brunda MJ, Wiltrout RH.

Ann N Y Acad Sci. 1996 Oct 31;795:434-9. No abstract available.

PMID:
8958976
39.
40.

The human ETS1 gene: genomic structure, promoter characterization and alternative splicing.

Jorcyk CL, Watson DK, Mavrothalassitis GJ, Papas TS.

Oncogene. 1991 Apr;6(4):523-32.

PMID:
2030910
41.

Molecular organization and differential polyadenylation sites of the human ETS2 gene.

Watson DK, Mavrothalassitis GJ, Jorcyk CL, Smyth FE, Papas TS.

Oncogene. 1990 Oct;5(10):1521-7.

PMID:
2250910
42.

Isoforms of the human ets-1 protein: generation by alternative splicing and differential phosphorylation.

Koizumi S, Fisher RJ, Fujiwara S, Jorcyk C, Bhat NK, Seth A, Papas TS.

Oncogene. 1990 May;5(5):675-81.

PMID:
2189104
43.

ETS family of genes in leukemia and Down syndrome.

Papas TS, Watson DK, Sacchi N, Fujiwara S, Seth AK, Fisher RJ, Bhat NK, Mavrothalassitis G, Koizumi S, Jorcyk CL, et al.

Am J Med Genet Suppl. 1990;7:251-61. Review.

PMID:
2149958
44.

A heat-shock-inducible eukaryotic expression vector.

Schweinfest CW, Jorcyk CL, Fujiwara S, Papas TS.

Gene. 1988 Nov 15;71(1):207-10.

PMID:
2850976
45.

A plasmid vector for cloning and expression of gene segments: expression of an HTLV-I envelope gene segment.

Sisk WP, Chirikjian JG, Lautenberger J, Jorcyk C, Papas TS, Berman ML, Zagursky R, Court DL.

Gene. 1986;48(2-3):183-93.

PMID:
2881844
46.

Diagnostic potential for human malignancies of bacterially produced HTLV-I envelope protein.

Samuel KP, Lautenberger JA, Jorcyk CL, Josephs S, Wong-Staal F, Papas TS.

Science. 1984 Nov 30;226(4678):1094-7.

PMID:
6208612

Supplemental Content

Loading ...
Support Center